Ariad Pharmaceuticals Inc. (ARIA) Financials Nov 2
Post# of 250663
Posted On: 11/20/2014 10:44:23 PM
Ariad Pharmaceuticals Inc. (ARIA) Financials Nov 20, 2014, 6:12 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Ariad Pharmaceuticals Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 8.3M 178.98M 25.3M 558,000 45.56M
Cost of Goods Sold (COGS) incl. D&A - - - - 9.61M
COGS excluding D&A - - - - 5.48M
Depreciation & Amortization Expense 4.22M 6.15M 4.61M 3.02M 4.14M
Depreciation 3.19M 5.27M 2.91M 2.8M 4.11M
Amortization of Intangibles 1.03M 880,000 1.7M 218,000 25,000
Gross Income - - - - 35.95M
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 76.12M 67.93M 97.51M 197.8M 304.72M
Research & Development 63.45M 57.99M 77.74M 139.91M 160.7M
Other SG&A 12.67M 9.95M 19.77M 57.89M 144.02M
Other Operating Expense 0 0 0 0 0
Unusual Expense 7.8M 19.53M 46.72M 20.72M 4.8M
EBIT after Unusual Expense (7.8M) (19.53M) (46.72M) (20.72M) (4.8M)
Non Operating Income/Expense 0 0 0 71,000 (130,000)
Non-Operating Interest Income 116,000 86,000 167,000 240,000 130,000
Equity in Affiliates (Pretax) 0 0 0 - 0
Interest Expense 287,000 206,000 232,000 199,000 153,000
Gross Interest Expense 287,000 206,000 232,000 199,000 153,000
Interest Capitalized 0 0 0 0 0
Pretax Income (80.01M) 85.25M (123.6M) (220.87M) (273.72M)
Income Tax 0 0 0 0 439,000
Income Tax - Current Domestic 0 0 - - 216,000
Income Tax - Current Foreign 0 0 0 - 223,000
Income Tax - Deferred Domestic 0 0 0 - -
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 0 0 0 - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (80.01M) 85.25M (123.6M) (220.87M) (274.16M)
Minority Interest Expense 0 0 0 0 0
Net Income (80.01M) 85.25M (123.6M) (220.87M) (274.16M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (80.01M) 85.25M (123.6M) (220.87M) (274.16M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (80.01M) 85.25M (123.6M) (220.87M) (274.16M)
EPS (Basic) (0.86) 0.75 (0.93) (1.34) (1.49)
Basic Shares Outstanding 93.33M 113.02M 132.38M 164.96M 183.58M
EPS (Diluted) (0.86) 0.74 (0.93) (1.34) (1.49)
Diluted Shares Outstanding 93.33M 114.73M 132.38M 164.96M 183.58M
EBITDA (67.81M) 111.05M (72.21M) (197.24M) (264.63M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Ariad Pharmaceuticals Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 8.3M 178.98M 25.3M 558,000 45.56M
Cost of Goods Sold (COGS) incl. D&A - - - - 9.61M
COGS excluding D&A - - - - 5.48M
Depreciation & Amortization Expense 4.22M 6.15M 4.61M 3.02M 4.14M
Depreciation 3.19M 5.27M 2.91M 2.8M 4.11M
Amortization of Intangibles 1.03M 880,000 1.7M 218,000 25,000
Gross Income - - - - 35.95M
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 76.12M 67.93M 97.51M 197.8M 304.72M
Research & Development 63.45M 57.99M 77.74M 139.91M 160.7M
Other SG&A 12.67M 9.95M 19.77M 57.89M 144.02M
Other Operating Expense 0 0 0 0 0
Unusual Expense 7.8M 19.53M 46.72M 20.72M 4.8M
EBIT after Unusual Expense (7.8M) (19.53M) (46.72M) (20.72M) (4.8M)
Non Operating Income/Expense 0 0 0 71,000 (130,000)
Non-Operating Interest Income 116,000 86,000 167,000 240,000 130,000
Equity in Affiliates (Pretax) 0 0 0 - 0
Interest Expense 287,000 206,000 232,000 199,000 153,000
Gross Interest Expense 287,000 206,000 232,000 199,000 153,000
Interest Capitalized 0 0 0 0 0
Pretax Income (80.01M) 85.25M (123.6M) (220.87M) (273.72M)
Income Tax 0 0 0 0 439,000
Income Tax - Current Domestic 0 0 - - 216,000
Income Tax - Current Foreign 0 0 0 - 223,000
Income Tax - Deferred Domestic 0 0 0 - -
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 0 0 0 - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (80.01M) 85.25M (123.6M) (220.87M) (274.16M)
Minority Interest Expense 0 0 0 0 0
Net Income (80.01M) 85.25M (123.6M) (220.87M) (274.16M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (80.01M) 85.25M (123.6M) (220.87M) (274.16M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (80.01M) 85.25M (123.6M) (220.87M) (274.16M)
EPS (Basic) (0.86) 0.75 (0.93) (1.34) (1.49)
Basic Shares Outstanding 93.33M 113.02M 132.38M 164.96M 183.58M
EPS (Diluted) (0.86) 0.74 (0.93) (1.34) (1.49)
Diluted Shares Outstanding 93.33M 114.73M 132.38M 164.96M 183.58M
EBITDA (67.81M) 111.05M (72.21M) (197.24M) (264.63M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
(0)
(0)